Dev Anouk, Patel Keyur, McHutchison John G
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Centre, P.O. Box 17969, Durham, NC 27715, USA.
Clin Liver Dis. 2004 Nov;8(4):881-92, ix. doi: 10.1016/j.cld.2004.06.007.
Steatosis is a common finding in patients with chronic hepatitis C (CHC) due to a combination of the direct steatogenic effect of hepatitis C virus (HCV) and the prevalence of metabolic risk factors in the HCV population. Steatosis is now established as a risk factor for disease progression in CHC and significantly impacts therapeutic response. Research efforts should continue to focus on defining the complex viral and host interactions involved in the pathogenesis of HCV-related steatosis so that future therapeutic strategies may be accurately and appropriately targeted.
由于丙型肝炎病毒（HCV）的直接致脂作用以及HCV人群中代谢危险因素的普遍存在，脂肪变性在慢性丙型肝炎（CHC）患者中很常见。脂肪变性现已被确认为CHC疾病进展的危险因素，并对治疗反应有显著影响。研究工作应继续集中于确定HCV相关脂肪变性发病机制中复杂的病毒与宿主相互作用，以便未来的治疗策略能够准确且适当地靶向这些作用。
